Gabather AB (DE:5J2)
FRANKFURT:5J2
5J2 Stock Chart & Stats
€0.01
>-€0.01(-5.13%)
At close: 4:00 PM EST
€0.01
>-€0.01(-5.13%)
Day’s Range― - ―
52-Week Range€0.00 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)1.71K
Market Cap
€2.15M
Enterprise Value€6.78M
Total Cash (Recent Filing)€3.14M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta4.44
Next Earnings
May 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding491,634,160
10 Day Avg. Volume1,710
30 Day Avg. Volume1,710
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-6.10
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Reported DebtThe company reports no debt, which materially lowers fixed financing obligations and bankruptcy risk. For a pre-revenue drug developer this durable structural feature preserves strategic optionality for R&D financing, giving management flexibility in capital structure choices.
Improving Net Loss TrendA steady narrowing of annual net losses over multiple years indicates successful cost discipline or program reprioritization. This persistent downward trend enhances medium-term sustainability of operations and reduces the size of future financing needs if maintained.
Demonstrated Ability To Cut Operating Cash BurnManagement previously reduced operating cash outflows materially between 2023 and 2024, showing the ability to control program spending. This operational responsiveness is a durable managerial capability that can extend runway and improve financing flexibility when applied consistently.
Bears Say
Pre-revenue With Persistent Cash BurnThe company remains pre-commercial with no reported revenue and sustained negative operating and free cash flow. Over the medium term this necessitates recurring external funding, increasing dilution or financing risk and making long-term product investment contingent on capital access.
Negative Shareholder EquityAccumulated losses have pushed equity into negative territory, weakening the balance sheet and limiting the company's ability to absorb further losses. Negative equity can hinder access to favorable financing and constrains strategic flexibility until recapitalized.
Volatile Asset Base And Cash-flow SwingsMaterial swings in total assets and year-to-year cash flow volatility signal unstable capitalization and program funding. Such structural variability complicates multi-year R&D planning, raises execution risk for clinical programs, and increases the likelihood of disruptive financing rounds.
5J2 FAQ
What was Gabather AB’s price range in the past 12 months?
Gabather AB lowest stock price was €0.00 and its highest was €0.01 in the past 12 months.
What is Gabather AB’s market cap?
Gabather AB’s market cap is €2.15M.
When is Gabather AB’s upcoming earnings report date?
Gabather AB’s upcoming earnings report date is May 28, 2026 which is in 56 days.
How were Gabather AB’s earnings last quarter?
Gabather AB released its earnings results on Feb 26, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.
Is Gabather AB overvalued?
According to Wall Street analysts Gabather AB’s price is currently Overvalued.
Does Gabather AB pay dividends?
Gabather AB does not currently pay dividends.
What is Gabather AB’s EPS estimate?
Gabather AB’s EPS estimate is 0.
How many shares outstanding does Gabather AB have?
Gabather AB has 491,634,160 shares outstanding.
What happened to Gabather AB’s price movement after its last earnings report?
Gabather AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went down -19.231%.
Which hedge fund is a major shareholder of Gabather AB?
Currently, no hedge funds are holding shares in DE:5J2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gabather AB
Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.
AlzeCure Pharma AB
―
Vivesto AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―